Xinyi Fang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Xinyi Fang has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Haoran Wu
Institute of Metabolic Diseases, China Academy of Chinese Medical Sciences Guang'anmen Hospital, Beijing, China
1 shared publication - Jiahua Wei
Changchun University of Chinese Medicine
1 shared publication - Jiaxing Tian
Department of Endocrinology, The Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, China
1 shared publication - Kaile Ma
Institute of Metabolic Diseases, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China
1 shared publication - Runyu Miao
Oncology Department of Integrative Medicine, China-Japan Friendship Hospital, Beijing, China
1 shared publication - Yanjiao Zhang
Institute of Metabolic Diseases, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China
1 shared publication
Latest Publications
- Open Access
- 30 November 2022
- Published by MDPI AG in Biomolecules
- Vol. 12 (12) , 1785
PDX-1: A Promising Therapeutic Target to Reverse Diabetes
The pancreatic duodenum homeobox-1 (PDX-1) is a transcription factor encoded by a Hox-like homeodomain gene that plays a crucial role in pancreatic development, β-cell differentiation, and the maintenance of mature β-cell functions. Research on the relationship between PDX-1 and diabetes has gained much attention because of the increasing prevalence of diabetes melitus (DM). Recent studies have shown that the overexpression of PDX-1 regulates pancreatic development and promotes β-cell differentiation and insulin secretion. It also plays a vital role in cell remodeling, gene editing, and drug development. Conversely, the absence of PDX-1 increases susceptibility to DM. Therefore, in this review, we summarized the role of PDX-1 in pancreatic development and the pathogenesis of DM. A better understanding of PDX-1 will deepen our knowledge of the pathophysiology of DM and provide a scientific basis for exploring PDX-1 as a potential target for treating diabetes.
- 30 November 2022
- Published by MDPI AG in Biomolecules
- Vol. 12 (12) , 1785
Open AccessPDX-1: A Promising Therapeutic Target to Reverse Diabetes
The pancreatic duodenum homeobox-1 (PDX-1) is a transcription factor encoded by a Hox-like homeodomain gene that plays a crucial role in pancreatic development, β-cell differentiation, and the maintenance of mature β-cell functions. Research on the relationship between PDX-1 and diabetes has gained much attention because of the increasing prevalence of diabetes melitus (DM). Recent studies have shown that the overexpression of PDX-1 regulates pancreatic development and promotes β-cell differentiation and insulin secretion. It also plays a vital role in cell remodeling, gene editing, and drug development. Conversely, the absence of PDX-1 increases susceptibility to DM. Therefore, in this review, we summarized the role of PDX-1 in pancreatic development and the pathogenesis of DM. A better understanding of PDX-1 will deepen our knowledge of the pathophysiology of DM and provide a scientific basis for exploring PDX-1 as a potential target for treating diabetes.